|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Paez JG, Jänne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et
al: EGFR mutations in lung cancer: Correlation with clinical
response to gefitinib therapy. Science. 304:1497–1500. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pao W, Miller V, Zakowski M, Doherty J,
Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, et al:
EGF receptor gene mutations are common in lung cancers from ‘never
smokers’ and are associated with sensitivity of tumors to gefitinib
and erlotinib. Proc Natl Acad Sci USA. 101:13306–13311. 2004.
View Article : Google Scholar
|
|
5
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et
al: Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S,
Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et
al; West Japan Oncology Group. Gefitinib versus cisplatin plus
docetaxel in patients with non-small-cell lung cancer harbouring
mutations of the epidermal growth factor receptor (WJTOG3405): An
open label, randomised phase 3 trial. Lancet Oncol. 11:121–128.
2010. View Article : Google Scholar
|
|
7
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al; North-East Japan Study Group. Gefitinib or chemotherapy for
non-small-cell lung cancer with mutated EGFR. N Engl J Med.
362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Moreira AL and Eng J: Personalized therapy
for lung cancer. Chest. 146:1649–1657. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Morgensztern D, Campo MJ, Dahlberg SE,
Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist
RS, Hensing T, et al: Molecularly targeted therapies in
non-small-cell lung cancer annual update 2014. J Thorac Oncol.
10:S1–S63. 2015. View Article : Google Scholar :
|
|
10
|
Califano R, Abidin A, Tariq NU,
Economopoulou P, Metro G and Mountzios G: Beyond EGFR and ALK
inhibition: Unravelling and exploiting novel genetic alterations in
advanced non small-cell lung cancer. Cancer Treat Rev. 41:401–411.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Regad T: Targeting RTK signaling pathways
in cancer. Cancers (Basel). 7:1758–1784. 2015. View Article : Google Scholar :
|
|
12
|
Trusolino L, Bertotti A and Comoglio PM:
MET signalling: Principles and functions in development, organ
regeneration and cancer. Nat Rev Mol Cell Biol. 11:834–848. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Roberts PJ and Der CJ: Targeting the
Raf-MEK-ERK mitogen-activated protein kinase cascade for the
treatment of cancer. Oncogene. 26:3291–3310. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
De Luca A, Maiello MR, D'Alessio A,
Pergameno M and Normanno N: The RAS/RAF/MEK/ERK and the PI3K/AKT
signalling pathways: Role in cancer pathogenesis and implications
for therapeutic approaches. Expert Opin Ther Targets. 16(Suppl 2):
S17–S27. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mizuuchi H, Suda K, Murakami I, Sakai K,
Sato K, Kobayashi Y, Shimoji M, Chiba M, Sesumi Y, Tomizawa K, et
al: Oncogene swap as a novel mechanism of acquired resistance to
epidermal growth factor receptor-tyrosine kinase inhibitor in lung
cancer. Cancer Sci. 107:461–468. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Togashi Y, Hayashi H, Terashima M, de
Velasco MA, Sakai K, Fujita Y, Tomida S, Nakagawa K and Nishio K:
Inhibition of β-catenin enhances the anticancer effect of
irreversible EGFR-TKI in EGFR-mutated non-small-cell lung cancer
with a T790M mutation. J Thorac Oncol. 10:93–101. 2015. View Article : Google Scholar
|
|
17
|
Network CGAR; Cancer Genome Atlas Research
Network. Comprehensive molecular profiling of lung adenocarcinoma.
Nature. 511:543–550. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Conde E, Angulo B, Tang M, Morente M,
Torres-Lanzas J, Lopez-Encuentra A, Lopez-Rios F and
Sanchez-Cespedes M: Molecular context of the EGFR mutations:
evidence for the activation of mTOR/S6K signaling. Clin Cancer Res.
12:710–717. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhou Y, Rideout WM III, Zi T, Bressel A,
Reddypalli S, Rancourt R, Woo JK, Horner JW, Chin L, Chiu MI, et
al: Chimeric mouse tumor models reveal differences in pathway
activation between ERBB family- and KRAS-dependent lung
adenocarcinomas. Nat Biotechnol. 28:71–78. 2010. View Article : Google Scholar
|
|
20
|
Karnoub AE and Weinberg RA: Ras oncogenes:
Split personalities. Nat Rev Mol Cell Biol. 9:517–531. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tsuta K, Kozu Y, Mimae T, Yoshida A, Kohno
T, Sekine I, Tamura T, Asamura H, Furuta K and Tsuda H:
c-MET/phospho-MET protein expression and MET gene copy number in
non-small cell lung carcinomas. J Thorac Oncol. 7:331–339. 2012.
View Article : Google Scholar
|
|
22
|
Tachibana K, Minami Y, Shiba-Ishii A, Kano
J, Nakazato Y, Sato Y, Goya T and Noguchi M: Abnormality of the
hepatocyte growth factor/MET pathway in pulmonary
adenocarcinogenesis. Lung Cancer. 75:181–188. 2012. View Article : Google Scholar
|
|
23
|
Sun W, Song L, Ai T, Zhang Y, Gao Y and
Cui J: Prognostic value of MET, cyclin D1 and MET gene copy number
in non-small cell lung cancer. J Biomed Res. 27:220–230. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Huang L, An SJ, Chen ZH, Su J, Yan HH and
Wu YL: MET expression plays differing roles in non-small-cell lung
cancer patients with or without EGFR mutation. J Thorac Oncol.
9:725–728. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bean J, Brennan C, Shih JY, Riely G, Viale
A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, et al: MET
amplification occurs with or without T790M mutations in EGFR mutant
lung tumors with acquired resistance to gefitinib or erlotinib.
Proc Natl Acad Sci USA. 104:20932–20937. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Engelman JA, Zejnullahu K, Mitsudomi T,
Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen
J, et al: MET amplification leads to gefitinib resistance in lung
cancer by activating ERBB3 signaling. Science. 316:1039–1043. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Beau-Faller M, Ruppert AM, Voegeli AC,
Neuville A, Meyer N, Guerin E, Legrain M, Mennecier B, Wihlm JM,
Massard G, et al: MET gene copy number in non-small cell lung
cancer: Molecular analysis in a targeted tyrosine kinase inhibitor
naive cohort. J Thorac Oncol. 3:331–339. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Onozato R, Kosaka T, Kuwano H, Sekido Y,
Yatabe Y and Mitsudomi T: Activation of MET by gene amplification
or by splice mutations deleting the juxtamembrane domain in primary
resected lung cancers. J Thorac Oncol. 4:5–11. 2009. View Article : Google Scholar
|
|
29
|
Cappuzzo F, Janne PA, Skokan M,
Finocchiaro G, Rossi E, Ligorio C, Zucali PA, Terracciano L, Toschi
L, Roncalli M, et al: MET increased gene copy number and primary
resistance to gefitinib therapy in non-small-cell lung cancer
patients. Ann Oncol. 20:298–304. 2009. View Article : Google Scholar :
|
|
30
|
Kubo T, Yamamoto H, Lockwood WW, Valencia
I, Soh J, Peyton M, Jida M, Otani H, Fujii T, Ouchida M, et al: MET
gene amplification or EGFR mutation activate MET in lung cancers
untreated with EGFR tyrosine kinase inhibitors. Int J Cancer.
124:1778–1784. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sequist LV, von Pawel J, Garmey EG,
Akerley WL, Brugger W, Ferrari D, Chen Y, Costa DB, Gerber DE,
Orlov S, et al: Randomized phase II study of erlotinib plus
tivantinib versus erlotinib plus placebo in previously treated
non-small-cell lung cancer. J Clin Oncol. 29:3307–3315. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dimou A, Non L, Chae YK, Tester WJ and
Syrigos KN: MET gene copy number predicts worse overall survival in
patients with non-small cell lung cancer (NSCLC); a systematic
review and meta-analysis. PLoS One. 9:e1076772014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lutterbach B, Zeng Q, Davis LJ, Hatch H,
Hang G, Kohl NE, Gibbs JB and Pan BS: Lung cancer cell lines
harboring MET gene amplification are dependent on Met for growth
and survival. Cancer Res. 67:2081–2088. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Spigel DR, Edelman MJ, O'Byrne K, Paz-Ares
L, Shames DS, Yu W, Paton VE and Mok T: Onartuzumab plus erlotinib
versus erlotinib in previously treated stage IIIb or IV NSCLC:
Results from the pivotal phase III randomized, multicenter,
placebo-controlled METLung (OAM4971g) global trial. J Clin Oncol.
32(Suppl 15): 80002014.
|
|
35
|
Li A, Gao HF and Wu YL: Targeting the MET
pathway for potential treatment of NSCLC. Expert Opin Ther Targets.
19:663–674. 2015. View Article : Google Scholar
|
|
36
|
Scagliotti G, von Pawel J, Novello S,
Ramlau R, Favaretto A, Barlesi F, Akerley W, Orlov S, Santoro A,
Spigel D, et al: Phase III multinational, randomized, double-blind,
placebo-controlled study of Tivantinib (ARQ 197) Plus Erlotinib
Versus Erlotinib alone in previously treated patients with locally
advanced or metastatic nonsquamous non-small-cell lung cancer. J
Clin Oncol. 33:2667–2674. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Camidge DS, Ou S-HI, Shapiro Geoffrey,
Otterson GA, Villaruz LC, Villalona-Calero MA, Iafrate AJ,
Varella-Garcia M, Dacic S, Cardarella S, et al: Efficacy and safety
of crizotinib in patients with advanced c-MET-amplified non-small
cell lung cancer (NSCLC). J Clin Oncol. 32(Suppl 15): 80012014.
|
|
38
|
Leiser D, Medová M, Mikami K, Nisa L,
Stroka D, Blaukat A, Bladt F, Aebersold DM and Zimmer Y: KRAS and
HRAS mutations confer resistance to MET targeting in preclinical
models of MET-expressing tumor cells. Mol Oncol. 9:1434–1446. 2015.
View Article : Google Scholar : PubMed/NCBI
|
